NRx Pharmaceuticals Seeks FDA Priority Voucher for Ketamine Treatment NRX-100

NRx Pharmaceuticals Inc. (NASDAQ: NRXP) has taken a significant step toward accelerating the approval of its preservative-free intravenous ketamine formulation, NRX-100, by applying for the FDA Commissioner’s National Priority Voucher (CNPV) program. This initiative is designed to fast-track the review of drugs that align with pressing national health needs, such as treatments for suicidal depression and PTSD. The company has submitted comprehensive Chemistry, Manufacturing, and Controls (CMC) data along with draft labeling for NRX-100, fulfilling key pre-qualification criteria for the voucher. NRx's efforts to manufacture NRX-100 in the U.S. aim to mitigate reliance on foreign supply chains and address concerns related to drug diversion. Additionally, the company holds a patent for the preservative-free process used in NRX-100 and has filed a citizen petition to withdraw preserved ketamine from the market, strategies that could strengthen its position in the competitive landscape. The FDA's CNPV program, announced by Commissioner Marty Makary, underscores the agency's commitment to prioritizing innovative treatments that meet critical health challenges. For more details on the CNPV program, visit https://ibn.fm/VeYud.